Summary

Significant pipeline of drugs – late stage trials – promising results
Substantial institutional buying over the last few weeks, about 30% ownership
Will regain NASDAQ compliance in about 6 days

Company

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) (Tonix) is a clinical-stage biopharmaceutical company committed to discovering and developing innovative and proprietary new therapeutics that address the needs of patients. We focus on developing small molecules and biologics to treat CNS (pain, neurology, psychiatry, addiction) and immunological (vaccines, immunosuppression, oncology, autoimmune disease) conditions.

Pipeline

TNX 102: A Fibromyalgia drug in phase 3 trials that already had positive results and it's estimated to be worth 2.8 billion.

https://www.globenewswire.com/news-release/2019/05/10/1821834/0/en/Fibromyalgia-Treatment-Market-to-Surpass-US-3-607-3-Million-by-2026-Coherent-Market-Insights.html

TNX 102 for Alzheimer’s

Currently, there are no FDA-approved treatments for AAD, despite a high disease burden and a need for an effective therapy. TNX-102 SL for the treatment of AAD has been designated by the FDA a Fast Track development program estimated to be worth 3.5 Billion

https://www.medgadget.com/2020/09/alzheimers-drugs-market-detailed-overview-market-analysis-manufacturers-and-latest-trends-forecast-to-2030.html

TNX 1800 COVID Vaccine

moving to human trials soon, already positive results. Uses t-cells which meaning anyone could get this vaccine.

https://www.tonixpharma.com/pipeline/tnx-1800-coronavirus-vaccine

Skin Test for COVID

https://finance.yahoo.com/news/tonix-pharmaceuticals-70m-plans-develop-181512513.html

Analysts

Price target of $3.00